The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease
NCT ID: NCT01809574
Last Updated: 2015-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2013-05-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Outcome and Prognostic Factors for Rheumatoid Arthritis (RA) Patients With Interstitial Lung Disease (ILD)
NCT03099525
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT03297775
Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Pathogenesis 2
NCT04227535
Interstitial Lung Disease in Early Rheumatoid Arthritis
NCT03977415
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NCT06732674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ILD according to ATS/ERS guidelines
* Signed inform consent
Exclusion Criteria
* Other significant systemic disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meir Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Shitrit, Dr
Role: PRINCIPAL_INVESTIGATOR
Head of Pulmonary departmant, Meir Medical Center.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Meir Medical Center
Kfar Saba, Israel, Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
225-12-MMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.